N. Kulahin,^{a,b,c,d,*} V. Kiselyov,^{a,b}
A. Kochoyan,^{a,c} O. Kristensen,^d
Jette S. Kastrup,^d V. Berezin,^a
E. Bock^a and M. Gajhede^d

^aProtein Laboratory, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark, ^bReceptor Systems Biology Laboratory, Hagedorn Research Institute, Copenhagen, Denmark, ^cENKAM Pharmaceuticals A/S, Copenhagen, Denmark, and ^dBiostructural Research, Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen, Denmark

Correspondence e-mail: kulahin@plab.ku.dk

Received 6 March 2008

Accepted 17 April 2008

PDB Reference: rat FGF1, 2uus, r2uussf.

Dimerization effect of sucrose octasulfate on rat FGF1

Fibroblast growth factors (FGFs) constitute a family of at least 23 structurally related heparin-binding proteins that are involved in regulation of cell growth, survival, differentiation and migration. Sucrose octasulfate (SOS), a chemical analogue of heparin, has been demonstrated to activate FGF signalling pathways. The structure of rat FGF1 crystallized in the presence of SOS has been determined at 2.2 Å resolution. SOS-mediated dimerization of FGF1 was observed, which was further supported by gel-filtration experiments. The major contributors to the sulfate-binding sites in rat FGF1 are Lys113, Lys118, Arg122 and Lys128. An arginine at position 116 is a consensus residue in mammalian FGF molecules; however, it is a serine in rat FGF1. This difference may be important for SOS-mediated FGF1 dimerization in rat.

1. Introduction

Fibroblast growth factors (FGFs) constitute a large family of signalling molecules that are involved in developmental processes, angiogenesis and tumour growth. At the cellular level, FGFs play important roles in cell differentiation, proliferation, migration and survival (Powers *et al.*, 2000; Ornitz & Itoh, 2001). The expression of different FGFs varies from ubiquitous for FGF2 to highly restricted for FGF4 (Basilico & Moscatelli, 1992). Mutations in FGFs or inappropriate protein expression are correlated with various pathological processes resulting in morphogenetic disorders and cancer (Takahashi *et al.*, 1992; Kornmann *et al.*, 1997). FGFs signal by activating their specific cell-surface receptors (FGFRs). Vertebrates have up to five FGFR paralogues (Powers *et al.*, 2000; Sleeman *et al.*, 2001). The diverse activities of FGFs are mediated by four receptor tyrosine kinases (FGFR1–FGFR4), each composed of an extracellular ligand-binding domain consisting of three immunoglobulin-like modules (Ig1–Ig3), a single transmembrane helix and a cytoplasmic part with protein tyrosine kinase activity (Ornitz *et al.*, 1996). For FGFRs 1–3, alternative splicing of the Ig3 domain results in two isoforms (IIIb and IIIc) with different ligand specificities. One receptor can bind and become activated by several FGF ligands.

Receptor dimerization and binding of heparin or heparan sulfate (HS) proteoglycans (HSPGs) are required for FGF signalling (Yayon *et al.*, 1991; Schlessinger, 2000). HS is produced in cells by modification of the initially synthesized polysaccharide backbone composed of *N*-acetyl glucosamine and glucuronic acid disaccharide units (Sugahara & Kitagawa, 2002). HS contains 40–300 saccharide units that are modified by a range of enzymes, replacing *N*-acetyl with *N*-sulfate, epimerizing glucuronic acid to iduronic acid and adding sulfate groups to iduronic acid or sulfate groups to the O6 glucosamine position. The final versions of HS usually consist of regions of up to 12–14 saccharide units with heavy modifications (NS domains), separated by stretches of 14–18 saccharide units with low levels of modification (S domains). Heparin is a mast-cell-derived analogue of HS that is more highly sulfated but with less complex sulfation patterns. Heparin can replace HS in FGF cellular signalling when HS has been removed by chlorate treatment. Hence, heparin has been

Table 1

Data-collection and processing statistics for the rat FGF1–SOS–FGF1 complex.

Values in parentheses are for the highest resolution shell.

X-ray source	BW7A, EMBL, Hamburg
Wavelength (Å)	0.8142
Space group	$P2_1$
Unit-cell parameters	
a (Å)	36.88
b (Å)	52.78
c (Å)	73.13
β (°)	97.43
Mosaicity (°)	0.7
Resolution (Å)	40.8–2.2 (2.32–2.20)
No. of observations	41588
No. of unique reflections	12293
Redundancy	3.4
Completeness (%)	98.4 (98.2)
$\langle I/\sigma(I) \rangle$	16.7 (7.0)
$R_{\text{merge}}^{\dagger}$ (%)	5.1 (19.2)
V_M (Å ³ Da ^{−1})	2.39
Refinement	
Protein atoms	2143
Protein residues	
Chain A	7–138
Chain B	8–138
Other atoms	163 waters, 1 sucrose octasulfate (55 atoms)
$R_{\text{work}}^{\ddagger}$ (%)	20.6
$R_{\text{free}}^{\S}$ (%)	27.7
Mean B values (Å ²)	
Molecule A	
Main chain	15.3
Side chain	23.0
Molecule B	
Main chain	22.7
Side chain	27.4
Water atoms	25.6
Sucrose octasulfate atoms	20.0
R.m.s.d. bond lengths (Å)	0.022
R.m.s.d. bond angles (°)	1.5

$\dagger R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the intensity of an individual measurement of the reflection with Miller indices hkl and $\langle I(hkl) \rangle$ is the mean intensity of that reflection. $\ddagger R_{\text{work}} = \sum_{hkl} ||F_{o,hkl}| - |F_{c,hkl}|| / \sum |F_{o,hkl}|$, where $|F_{o,hkl}|$ and $|F_{c,hkl}|$ are the observed and calculated structure-factor amplitudes, respectively. $\S R_{\text{free}}$ is equivalent to R_{work} , but calculated with reflections omitted from the refinement process (5% of reflections were omitted).

used for indirect studies of the interactions of FGFs with HS (Ornitz *et al.*, 1992; Walker *et al.*, 1994). Variations in the distribution of basic amino acids on the surface of FGFs result in FGF specificity towards different HS sulfate groups (Raman *et al.*, 2003).

Two contrasting models, symmetric and asymmetric, for FGFR dimerization have been proposed based on the crystal structures of FGF–FGFR–heparin complexes. In the symmetric model, two 1:1:1 FGF2–FGFR1–heparin complexes form a symmetric dimer (Plotnikov *et al.*, 1999; Ponting & Russell, 2000; Schlessinger *et al.*, 2000). Each FGF molecule is monomeric and binds to both receptor molecules in the dimer; direct contacts occur between the two FGFRs. In the complex, heparin binds to both the two FGFs and the two FGFRs, thereby enhancing FGF–FGFR affinity. In the asymmetric model derived from the FGF1–FGFR2–heparin structure, a single heparin oligosaccharide bridges two FGF molecules (forming a FGF–heparin–FGF complex with direct FGF–FGF interactions) that in turn facilitate dimerization of the receptor (Pellegrini *et al.*, 2000). Heparin binds only to one receptor molecule, resulting in asymmetry of the dimer. Unlike the configuration in the symmetric model, each FGF molecule contacts a single molecule of the receptor and no direct FGFR–FGFR contacts are observed. The total lack of a protein–protein interface between the two FGF–FGFR dimer complexes makes heparin necessary for receptor dimerization in the asymmetric model.

In addition to heparin, a number of chemically diverse low-molecular-weight and sulfated saccharides, such as sucrose octa-

sulfate (SOS), have been reported to potentiate FGF activity. SOS has been shown to mimic heparin action in supporting FGF-induced neoangiogenesis and cell proliferation *in vitro* (Folkman *et al.*, 1991; Arunkumar *et al.*, 2002; Loughman *et al.*, 1996; Yeh *et al.*, 2002). Moreover, SOS facilitates wound healing by enhancing FGF-induced angiogenesis (Rashid *et al.*, 1999). The molecular mechanism by which SOS stimulates FGF signalling is not fully understood. It has been demonstrated that SOS induces FGF–FGFR dimerization *in vitro*. The crystal structure of the human dimeric FGF–FGFR–SOS complex has also been published (Yeh *et al.*, 2002) and analysis of this dimeric structure reveals that SOS induces FGF–FGFR dimerization in a similar manner to the symmetric model. In accordance, the bovine FGF1–SOS crystal structure shows the presence of only one SOS molecule bound to the high-affinity heparin-binding site of one FGF1 molecule and thus does not indicate SOS-mediated FGF1 dimerization (Zhu *et al.*, 1993).

Here, we present the gel-filtration analysis and the crystal structure of rat FGF1 in complex with SOS, showing that rat FGF1 forms a SOS-mediated dimer in solution as well as in crystals. The interactions of SOS with FGF1 have been compared with those observed in the bovine complex, revealing new features of SOS binding.

2. Materials and methods

A cDNA fragment encoding rat FGF1 (residues 22–155; Swiss-Prot P61149) was synthesized by the polymerase chain reaction using Quick-Clone Rat Brain cDNA (BD Biosciences). The amplified cDNA fragment was subcloned into the *EcoRI/HindIII* cloning site of the pQE-60 plasmid (Qiagen). *Escherichia coli* strain Top10F' (Invitrogen) was used for transformation. Expression of the protein was induced by adding isopropyl β -D-1-thiogalactopyranoside (IPTG; Sigma). The protein was purified by affinity chromatography using a 5 ml HiTrap Heparin HP column (GE Healthcare).

Protein crystallization was performed in hanging-drop vapour-diffusion experiments by mixing 1 μ l protein solution (1 mM rat FGF1 solution containing 0.5–1 mM SOS) and 1 μ l reservoir solution (10% PEG 6000, 0.1 M citric acid pH 5.0). Crystals were obtained at room temperature within 2 d. X-ray data were collected at 100 K

Figure 1

The rat FGF1–SOS–FGF1 ternary complex observed in the crystal structure. Both direct and SOS-mediated FGF1–FGF1 interactions are observed. A $2F_o - F_c$ electron-density map around SOS contoured at 1σ is shown in grey.

The FGF1-SOS structure was determined by the molecular-replacement method using the program *Phaser* (Storoni *et al.*, 2004). A crystal structure of rat FGF1 (molecule *A*, PDB code 2j3p; Kulahin *et al.*, 2007) was used as a search model and solutions accounting for the two molecules in the asymmetric unit were obtained. Subsequently, automated model building was performed using the program *ARP/wARP* (Perrakis *et al.*, 1999). This resulted in the tracing of 95% of the residues. The missing residues were inserted manually using the program *Coot* (Emsley & Cowtan, 2004). Structure refinement was performed with the program *REFMAC5* (Murshudov *et al.*, 1999). Water molecules and a single SOS molecule were gradually introduced into the structure. The quality of the structure was evaluated

Gel-filtration experiments were performed either in phosphate-buffered saline (PBS) or in PBS with 0.0362 mM SOS using a Superdex 75 column (GE Healthcare).

3.1. Structure of the rat FGF1–SOS–FGF1 complex

SOS interacts with both FGF1 molecules in the asymmetric unit. The interaction area comprises both protein–protein and protein–SOS–protein contacts. The interactions in the crystal were analyzed

(a) Ligplot showing interactions in the FGF1-SOS-FGF1 ternary complex. The interactions are dominated by salt bridges. (b) Stereo plot of a superposition of rat FGF1-SOS-FGF1 (blue C atoms) and bovine FGF1-SOS (green C atoms). Only residues within 5 Å from SOS are included and interacting basic residues are labelled.

using the *PISA* server (Krissinel & Henrick, 2007). The FGF1(A)–SOS–FGF1(B) complex observed in the crystal is classified as a possible solution multimer, with a total buried accessible surface area of 1500 Å². Two additional minor FGF1–FGF1 crystal contact areas of 1180 and 960 Å² were found.

Direct hydrogen-bonding interactions between the two FGF1 molecules and the highly charged SOS molecule are shown schematically in Fig. 2(a), which was generated with the programs *LIGPLOT* (Wallace *et al.*, 1995) and *HBPLUS* (McDonald & Thornton, 1994). A total of 11 residues make interactions with seven of the eight sulfate groups of SOS. Seven of the 11 interacting residues are basic: three and four from the A and B chains, respectively. This suggests that SOS invokes strong electrostatic interactions within the ternary FGF1–SOS–FGF1 complex.

3.2. Gel filtration of rat FGF1 in the presence of SOS

Gel filtration of rat FGF1 produced a single symmetrical peak corresponding to the monomeric form of the protein (Fig. 3; red colour). When the gel-filtration column was pre-equilibrated with SOS-containing buffer (2:1 FGF1:SOS molar ratio), FGF1 was eluted as a single peak with the elution volume reduced by 7 ml, corresponding to the dimeric form of the protein (Fig. 3; blue colour).

4. Discussion

The present study was undertaken to investigate if and how rat FGF1 interacts with the heparin mimic SOS. From gel-filtration experiments, we estimated the molar weight of rat FGF1 to be ~13 kDa (Fig. 3), compared with the calculated value of 17.4 kDa. After the addition of SOS (MW ≈ 1.1 kDa) to a 2:1 FGF1:SOS molar ratio, a single peak corresponding to a molar weight of 22 kDa was observed. Even though rat FGF1 runs more slowly than expected, the experiment clearly suggests that a ternary FGF1–SOS–FGF1 complex is formed in solution.

The existence of the FGF1(A)–SOS–FGF1(B) ternary complex was confirmed by X-ray crystallography. A similar ternary complex was not observed in the bovine FGF1–SOS structure (Zhu *et al.*, 1993). Superimposition of the rat FGF1–SOS–FGF1 complex and the bovine FGF1–SOS complex reveals that the binding modes are quite different (Fig. 2b) and that only two of the sulfates occupy similar

positions. In the rat structure, the SOS furanose ring approximately occupies the position of the pyranose ring of the bovine complex. The residues forming the major sulfate-binding sites in bovine FGF1 are Arg116, Lys118 and Arg122. Interestingly, whereas arginine is the consensus residue at this position in mammalian FGF molecules, it is a serine in rat FGF1. Instead, the major contributors to the sulfate-binding sites in rat FGF1 are Lys113, Lys118, Arg122 and Lys128. This difference might explain why SOS-mediated FGF1 dimerization is seen in rat and suggests that SOS functions differently in rats and cattle. A further consequence of SOS-mediated FGF1 dimerization in rat is that it suggests that SOS-induced activation of rat FGFR follows the asymmetric model.

The beamline scientists at EMBL, Hamburg, Germany are gratefully acknowledged for their technical support. This work was supported by grants from DANSYNC (Danish Center for Synchrotron-Based Research), the Danish Medical Research Council, the Lundbeck Foundation and the European Community 'Sixth Framework Programme' Promemoria.

References

- Arunkumar, A. I., Kumar, T. K., Kathir, K. M., Srisailam, S., Wang, H. M., Leena, P. S., Chi, Y. H., Chen, H. C., Wu, C. H., Wu, R. T., Chang, G. G., Chiu, I. M. & Yu, C. (2002). *Protein Sci.* **11**, 1050–1061.
- Basilico, C. & Moscatelli, D. (1992). *Adv. Cancer Res.* **59**, 115–165.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- DeLano, W. L. (2002). *Curr. Opin. Struct. Biol.* **12**, 14–20.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
- Folkman, J., Szabo, S., Stovroff, M., McNeil, P., Li, W. & Shing, Y. (1991). *Ann. Surg.* **214**, 414–425.
- Kornmann, M., Ishiwata, T., Beger, H. G. & Korc, M. (1997). *Oncogene*, **15**, 1417–1424.
- Krissinel, E. & Henrick, K. (2007). *J. Mol. Biol.* **372**, 774–797.
- Kulahin, N., Kiselyov, V., Kochoyan, A., Kristensen, O., Kastrup, J. S., Berezin, V., Bock, E. & Gajhede, M. (2007). *Acta Cryst.* **F63**, 65–68.
- Laskowski, R. A., Moss, D. S. & Thornton, J. M. (1993). *J. Mol. Biol.* **231**, 1049–1067.
- Loughman, M. S., Chatzistefanou, K., Gonzalez, E. M., Flynn, E., Adamis, A. P., Shing, Y., D'Amato, R. J. & Folkman, J. (1996). *Aust. N. Z. J. Ophthalmol.* **24**, 289–295.
- McDonald, I. K. & Thornton, J. M. (1994). *J. Mol. Biol.* **238**, 777–793.
- Murshudov, G. N., Vagin, A. A., Lebedev, A., Wilson, K. S. & Dodson, E. J. (1999). *Acta Cryst.* **D55**, 247–255.
- Ornitz, D. M. & Itoh, N. (2001). *Genome Biol.* **2**, REVIEWS3005.
- Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G. & Goldfarb, M. (1996). *J. Biol. Chem.* **271**, 15292–15297.
- Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E. & Leder, P. (1992). *Mol. Cell. Biol.* **12**, 240–247.
- Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B. & Blundell, T. L. (2000). *Nature (London)*, **407**, 1029–1034.
- Perrakis, A., Morris, R. & Lamzin, V. S. (1999). *Nature Struct. Biol.* **6**, 458–463.
- Plotnikov, A. N., Schlessinger, J., Hubbard, S. R. & Mohammadi, M. (1999). *Cell*, **98**, 641–650.
- Ponting, C. P. & Russell, R. B. (2000). *J. Mol. Biol.* **302**, 1041–1047.
- Powers, C. J., McLuskey, S. W. & Wellstein, A. (2000). *Endocr. Relat. Cancer*, **7**, 165–197.
- Raman, R., Venkataraman, G., Ernst, S., Sasisekharan, V. & Sasisekharan, R. (2003). *Proc. Natl Acad. Sci. USA*, **100**, 2357–2362.
- Rashid, M. A., Akita, S., Razzaque, M. S., Yoshimoto, H., Ishihara, H., Fujii, T., Tanaka, K. & Taguchi, T. (1999). *Plast. Reconstr. Surg.* **103**, 941–948.
- Schlessinger, J. (2000). *Cell*, **103**, 211–225.
- Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J. & Mohammadi, M. (2000). *Mol. Cell*, **6**, 743–750.
- Sleeman, M., Fraser, J., McDonald, M., Yuan, S., White, D., Grandison, P., Kumble, K., Watson, J. D. & Murison, J. G. (2001). *Gene*, **271**, 171–182.
- Storoni, L. C., McCoy, A. J. & Read, R. J. (2004). *Acta Cryst.* **D60**, 432–438.
- Sugahara, K. & Kitagawa, H. (2002). *IUBMB Life*, **54**, 163–175.

Figure 3
Gel-filtration analysis, demonstrating the dimerization effect of SOS on rat FGF1 in solution. Gel-filtration experiments were performed either in PBS (peak shown in red) or in PBS with 0.0362 mM SOS (peak shown in blue) using a Superdex 75 column. Elution peaks corresponding to aprotinin (6.5 kDa), ribonuclease A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (43 kDa), conalbumin (75 kDa) and blue dextran (void volume) are shown in black.

- Takahashi, J. A., Fukumoto, M., Igarashi, K., Oda, Y., Kikuchi, H. & Hatanaka, M. (1992). *J. Neurosurg.* **76**, 792–798.
- Walker, A., Turnbull, J. E. & Gallagher, J. T. (1994). *J. Biol. Chem.* **269**, 931–935.
- Wallace, A. C., Laskowski, R. A. & Thornton, T. M. (1995). *Protein Eng.* **8**, 127–134.
- Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P. & Ornitz, D. M. (1991). *Cell*, **64**, 841–848.
- Yeh, B. K., Eliseenkova, A. V., Plotnikov, A. N., Green, D., Pinnell, J., Polat, T., Gritli-Linde, A., Linhardt, R. J. & Mohammadi, M. (2002). *Mol. Cell. Biol.* **22**, 7184–7192.
- Zhu, X., Hsu, B. T. & Rees, D. C. (1993). *Structure*, **1**, 27–34.